IDentaIDTA 44 Return-on-Tangible-Equity is 13.09% as of Mar. 2026, which is 52% below its 10-year median of 27.28. GuruFocus rates IDTA with a GF Score™ of 44/100 and a GF Value™ of $0.35 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 194 Medical Diagnostics & Research companies, IDenta ranks better than 76.29% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. IDenta's annualized net income for the quarter that ended in Mar. 2026 was $0.12 Mil. IDenta's average shareholder tangible equity for the quarter that ended in Mar. 2026 was $0.92 Mil. Therefore, IDenta's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 13.09%.
The historical rank and industry rank for IDenta's Return-on-Tangible-Equity or its related term are showing as below:
IDTA'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 3.07 Med: 27.28 Max: 219.2
Current: 23.31
During the past 8 years, IDenta's highest Return-on-Tangible-Equity was 219.20%. The lowest was 3.07%. And the median was 27.28%.
IDTA's Return-on-Tangible-Equity is ranked better than 76.29% of 194
companies
in the Medical Diagnostics & Research industry
Industry Median: -0.405
vs IDTA: 23.31
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
IDenta Return-on-Tangible-Equity Related Terms
IDenta Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for IDenta's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IDTA vs NSTM, PRPH, NOTVQ: Return-on-Tangible-Equity Comparison
For the Diagnostics & Research subindustry, IDenta's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IDenta Return-on-Tangible-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, IDenta's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where IDenta's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 13.09% mean?
IDenta (IDTA) has a Return-on-Tangible-Equity of 13.09% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on IDenta and its competitors. This is 52% below median its historical median of 27.28. Over the past decade, IDenta's Return-on-Tangible-Equity has ranged from 3.07 to 219.20. According to the industry distribution chart, IDenta ranks #46 out of 194 companies in the Medical Diagnostics & Research industry, placing it in the top 23.7%.
Is IDenta's Return-on-Tangible-Equity too high?
IDenta's current Return-on-Tangible-Equity of 13.09% is 52% below median its 10-year median of 27.28. Over the past 10 years, this metric has ranged from a low of 3.07 to a high of 219.20. Based on the distribution chart, IDenta ranks #46 out of 194 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, IDenta has a GF Score™ of 44/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IDenta's Return-on-Tangible-Equity compare to NSTM and PRPH?
According to the Medical Diagnostics & Research industry distribution chart, IDenta ranks #46 out of 194 companies for Return-on-Tangible-Equity. This places IDenta in the top 24% of its industry — outperforming the majority of peers. Historically, IDenta's own Return-on-Tangible-Equity has ranged from 3.07 to 219.20 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Diagnostics & Research company?
A good Return-on-Tangible-Equity depends on the Medical Diagnostics & Research industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on IDenta and its competitors. IDenta's current Return-on-Tangible-Equity is 13.09%, which is 52% below median its own 10-year median of 27.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDenta stock overvalued right now?
Based on GuruFocus' analysis, IDenta (IDTA) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.35, compared to a current price of $0.28 — trading 21.4% below its estimated fair value. The current Return-on-Tangible-Equity is 13.09%, which is 52% below median its 10-year median of 27.28. IDenta's overall GF Score™ is 44/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For IDenta (IDTA), the current Return-on-Tangible-Equity is 13.09% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IDenta (IDTA) Overvalued in 2026?
Based on GuruFocus' analysis, IDenta stock appears to be undervalued.
The current stock price of $0.28 is trading 21.4% below its estimated GF Value™ of $0.35.
GuruFocus considers IDenta to be Modestly Undervalued.
Key valuation signals for IDTA:
Return-on-Tangible-Equity: 13.09% (52% below median its 10-year median of 27.28)
GF Value™: $0.35 vs. price of $0.28 (21.4% below fair value)
No single metric tells the full story. See the IDTA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IDenta Corp is a detection and forensic science company. The firm, through its subsidiary, is engaged in the business of developing products to test for the presence of illegal drugs and explosives for law enforcement agencies, ports and border crossings, shipping hubs, and other organizations. Its product portfolio includes Drug testing kits, Explosive testing kits, Forensic products, Urine drug testing and others. The company currently sells its products to law enforcement organizations in the following countries: Indonesia, Argentina, Poland, France, USA, Spain, India, the United Kingdom, Ghana, Nigeria, Australia, Russia, Israel, Canada, Germany, Italy, and Portugal. The company also sells to retail markets in the United States, Italy, and South Africa.
44GF Score
Get the complete analysis for IDTA
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IDTA has been successfully added to your 
